|
WO2014013008A1
|
|
Gastro-resistant delayed release pharmaceutical form
|
|
WO2014013006A1
|
|
Multilayered pharmaceutical formulation
|
|
EP2268617A1
|
|
Process for the resolution of isoquinoline derivatives
|
|
WO2008077866A1
|
|
Process for manufacturing microcrystalline lansoprazole form i
|
|
WO2007025780A2
|
|
Aldosterone receptor antagonists
|
|
US7189876B2
|
|
Methods for preparing sertraline hydrochloride polymorphs
|
|
US7173153B2
|
|
Sertraline hydrochloride form II and methods for the preparation thereof
|
|
WO2004067002A2
|
|
SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT
|
|
US2004215284A1
|
|
Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists
|
|
AU2003249964A1
|
|
A process for the preparation of 2-acetoxymethyl-4 halo-but-1-yl acetates
|
|
WO03106421A2
|
|
Phenylalkylamines and pyridylalkylamines with serotoninergic receptor affinity
|
|
US7071197B2
|
|
N,N-disubstituted diazocycloalkanes
|
|
TW200406212A
|
|
Diastereoselective process for the preparation of the antiviral agent 4-amino-1-(2R-hydroxymethyl-[1-3]oxathiolan-5S-yl)-1H-pyrimidin-2-one
|
|
OA12663A
|
|
Heterocyclic compounds for use in the treatment ofdisorders of the urinary tract.
|
|
US2002193383A1
|
|
1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring
|
|
CA2380202A1
|
|
Novel crude and crystalline forms of lercanidipine hydrochloride
|
|
WO02060534A2
|
|
Selective alpha 1 antagonists a + d
|
|
US2002183290A1
|
|
Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor
|
|
US6440963B1
|
|
Use of selective COX-2 inhibitors for the treatment of urinary incontinence
|
|
US6365591B1
|
|
Isoxazolecarboxamide derivatives
|
